In Brief: Redux
This article was originally published in The Tan Sheet
Executive Summary
Redux: Prescription anti-obesity drug approved by FDA on April 29. Wyeth-Ayerst and Interneuron will introduce the product in June 1996. The cost of Redux (dexfenfluramine) to the patient will be approximately $2.40 per day. It will be available in 15 mg capsules, to be taken twice daily. Redux is scheduled by the Drug Enforcement Agency as Category IV, meaning "low potential for abuse." Prescription restrictions for Category IV drugs allow "up to five renewals" within a six month period. Weight loss company Jenny Craig is planning a test program using Redux in at least one market when the compound becomes available...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning